During European Myeloma Day, MPE highlights the importance of improving access to clinical trialsAccess, MPE, MyelomaSeptember 27, 2024
ASH 2023 | Myeloma and AL amyloidosis updatesAL amyloidosis, Conferences, MPE, MyelomaDecember 15, 2023
Register now for MPE’s webinar on Evidence-Based Patient AdvocacyMPE, Patient evidenceOctober 19, 2020
MPE launches a report focused on the impact of AL amyloidosis in quality of lifeAL amyloidosis, MPENovember 21, 2023
WECAN workgroup of patient advocates and industry experts releases guiding principles for reasonable legal agreements between patient advocates and pharmaceutical companiesMPENovember 28, 2018
Q&A: US Food and Drug Administration (FDA) approves MRD as a basis for accelerated approval in myelomaAccess, MPE, MyelomaApril 18, 2024
MPE comments on the second implementing act of the EU health technology assessment (HTA) regulation (EU HTAR)Access, MPEJune 26, 2024
Sign up for the MPE webinar on EHA myeloma and AL amyloidosis highlights AL amyloidosis, Conferences, MPE, MyelomaJune 14, 2023
